The Europe Onychomycosis Market should witness market growth of 4.6% CAGR during the forecast period (2022-2028).
Onychomycosis cansignificantly impair a patient's ability to function emotionally, socially, and at work, as well as cost a large amount in terms of medical expenses. Patients with the condition may feel embarrassed in social and professional settings, feeling blighted or filthy and hesitant to allow their feet orhands to be seen. Patients may worry that they may spread their virus to family, friends, or coworkers; these worries can lower self-esteem and cause patients to shun close connections.
If employers avoid hiring people with unusual nails, especially for positions requiring public engagement, like food handling or modeling, employment decreases. The distress some patients endure that prohibits them from performing work-related duties like writing, prolonged standing,or typing is a more obvious obstacle to career success.
The market is growing as a consequence of myriad of factors such as the rising incidence of chronic diseases, increased R&D for the development of novel treatments, and a rise in the proportion of elderly people. The growing number of diabetics in the world also propagate the chances of acquiring onychomycosis. The need for treatments is generally recognised due to the prevalence of onychomycosis infections worldwide. Additionally, larger companies are diversifying their portfolio of antifungal medications through acquisition strategies.
Due to the rising incidence of onychomycosis, favorable health reimbursement policies, and enhanced distribution of OTC medications through partnerships with retail pharmacies like Walmart, Walgreens, and others, the need for dermatophytic onychomycosis therapy is projected to increase in Europe. Onychomycosis is widelycommon throughout Europe, according to a study published in the Journal of the European Academy of Dermatology and Venereology. Since manyEuropean countries wereamong the worst hit by the coronavirus pandemic, like Spain,Italy, Britain, etc.,the occurrence of onychomycosis increased slightly.During the forecast period, these factors are anticipated to be favorable for the onychomycosis market in the European region.
The Germany market dominated the Europe Onychomycosis Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $300.7 Million by 2028. The UK market is anticipated to grow at a CAGR of 3.7% during (2022-2028). Additionally, The France market would exhibit a CAGR of 5.3% during (2022-2028).
Based on Type, the market is segmented into Distal Subungual, Proximal Subungual, White Superficial and Others. Based on Treatment, the market is segmented into Topical, Oral and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Abbott Laboratories, Bausch Health Companies, Inc., Bayer AG, Cipla Limited, Merck & Co., Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., and GlaxoSmithKline PLC.
Onychomycosis cansignificantly impair a patient's ability to function emotionally, socially, and at work, as well as cost a large amount in terms of medical expenses. Patients with the condition may feel embarrassed in social and professional settings, feeling blighted or filthy and hesitant to allow their feet orhands to be seen. Patients may worry that they may spread their virus to family, friends, or coworkers; these worries can lower self-esteem and cause patients to shun close connections.
If employers avoid hiring people with unusual nails, especially for positions requiring public engagement, like food handling or modeling, employment decreases. The distress some patients endure that prohibits them from performing work-related duties like writing, prolonged standing,or typing is a more obvious obstacle to career success.
The market is growing as a consequence of myriad of factors such as the rising incidence of chronic diseases, increased R&D for the development of novel treatments, and a rise in the proportion of elderly people. The growing number of diabetics in the world also propagate the chances of acquiring onychomycosis. The need for treatments is generally recognised due to the prevalence of onychomycosis infections worldwide. Additionally, larger companies are diversifying their portfolio of antifungal medications through acquisition strategies.
Due to the rising incidence of onychomycosis, favorable health reimbursement policies, and enhanced distribution of OTC medications through partnerships with retail pharmacies like Walmart, Walgreens, and others, the need for dermatophytic onychomycosis therapy is projected to increase in Europe. Onychomycosis is widelycommon throughout Europe, according to a study published in the Journal of the European Academy of Dermatology and Venereology. Since manyEuropean countries wereamong the worst hit by the coronavirus pandemic, like Spain,Italy, Britain, etc.,the occurrence of onychomycosis increased slightly.During the forecast period, these factors are anticipated to be favorable for the onychomycosis market in the European region.
The Germany market dominated the Europe Onychomycosis Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $300.7 Million by 2028. The UK market is anticipated to grow at a CAGR of 3.7% during (2022-2028). Additionally, The France market would exhibit a CAGR of 5.3% during (2022-2028).
Based on Type, the market is segmented into Distal Subungual, Proximal Subungual, White Superficial and Others. Based on Treatment, the market is segmented into Topical, Oral and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Abbott Laboratories, Bausch Health Companies, Inc., Bayer AG, Cipla Limited, Merck & Co., Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., and GlaxoSmithKline PLC.
Scope of the Study
By Type
- Distal Subungual
- Proximal Subungual
- White Superficial
- Others
By Treatment
- Topical
- Oral
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Abbott Laboratories
- Bausch Health Companies, Inc.
- Bayer AG
- Cipla Limited
- Merck & Co., Inc.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- GlaxoSmithKline PLC
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Onychomycosis Market, by Type
1.4.2 Europe Onychomycosis Market, by Treatment
1.4.3 Europe Onychomycosis Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Europe Onychomycosis Market by Type
3.1 Europe Distal Subungual Market by Country
3.2 Europe Proximal Subungual Market by Country
3.3 Europe White Superficial Market by Country
3.4 Europe Others Market by Country
Chapter 4. Europe Onychomycosis Market by Treatment
4.1 Europe Topical Market by Country
4.2 Europe Oral Market by Country
4.3 Europe Others Market by Country
Chapter 5. Europe Onychomycosis Market by Country
5.1 Germany Onychomycosis Market
5.1.1 Germany Onychomycosis Market by Type
5.1.2 Germany Onychomycosis Market by Treatment
5.2 UK Onychomycosis Market
5.2.1 UK Onychomycosis Market by Type
5.2.2 UK Onychomycosis Market by Treatment
5.3 France Onychomycosis Market
5.3.1 France Onychomycosis Market by Type
5.3.2 France Onychomycosis Market by Treatment
5.4 Russia Onychomycosis Market
5.4.1 Russia Onychomycosis Market by Type
5.4.2 Russia Onychomycosis Market by Treatment
5.5 Spain Onychomycosis Market
5.5.1 Spain Onychomycosis Market by Type
5.5.2 Spain Onychomycosis Market by Treatment
5.6 Italy Onychomycosis Market
5.6.1 Italy Onychomycosis Market by Type
5.6.2 Italy Onychomycosis Market by Treatment
5.7 Rest of Europe Onychomycosis Market
5.7.1 Rest of Europe Onychomycosis Market by Type
5.7.2 Rest of Europe Onychomycosis Market by Treatment
Chapter 6. Company Profiles
6.1 Abbott Laboratories
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.1.5 SWOT Analysis
6.2 Bausch Health Companies, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.2.5 Recent strategies and developments:
6.2.5.1 Trials and Approvals:
6.3 Bayer AG
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.3.5 Recent strategies and developments:
6.3.5.1 Product Launches and Expansions:
6.4 Cipla Limited
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expense
6.4.5 Recent strategies and developments:
6.4.5.1 Product Launches and Product Expansions:
6.5 Sun Pharmaceutical Industries Ltd.
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Regional & Segmental Analysis
6.5.4 Research & Development Expenses
6.5.5 Recent strategies and developments:
6.5.5.1 Acquisition and Mergers:
6.6 GlaxoSmithKline PLC (GSK)
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.6.5 Recent strategies and developments:
6.6.5.1 Partnerships, Collaborations, and Agreements:
6.7 Pfizer, Inc.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional & Segmental Analysis
6.7.4 Research & Development Expense
6.8 Teva Pharmaceutical Industries Ltd.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expenses
6.9 Merck & Co., Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expenses
6.10. Novartis AG
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Segmental and Regional Analysis
6.10.4 Research & Development Expense
Companies Mentioned
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Abbott Laboratories
- Bausch Health Companies, Inc.
- Bayer AG
- Cipla Limited
- Merck & Co., Inc.
- Novartis AG
- Sun Pharmaceutical Industries Ltd.
- GlaxoSmithKline PLC
Methodology
LOADING...
